Furthermore, the Clta-reporter can be also used to investigate the bioavailability of CME inhibitors (e.g. in schizophrenia and bipolar disorders [65]) or to monitor drug delivery via CME of nanoparticle delivered drugs [66]. This evidence concerns the gene CLTA and bipolar disorder.